Multinational biopharmaceutical company Celgene has received US Food and Drug Administration (FDA) approval for Abraxane, which is aimed to treat locally advanced or metastatic non-small cell lung cancer in combination with carboplatin in ...
Tags: Abraxane, lung cancer, Multinational biopharmaceutical company Celgene
Proacta, a San Diego based biotechnology company, has announced FDA approval of investigational new drug (IND) application for PR610, a hypoxia-activated irreversible multi-kinase inhibitor, for the treatment of cancer. With the IND ...
Tags: investigational new drug, IND
The European Commission has granted conditional marketing authorization for Pfizer’s Xalkori (crizotinib) to treat anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) in the European Union (EU). ...
Tags: Xalkori, crizotinib, anaplastic lymphoma kinase, ALK
Cytocell, a developer of fluorescence in situ hybridization (FISH) probes for use in cancer analysis, has unveiled a ROS1 Breakapart FISH probe test for non-small-cell lung cancer (NSCLC). The molecular cytogenetic test, which utilizes ...
Pfizer has received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for crizotinib to treat adults with previously treated anaplastic lymphoma kinase (ALK)-positive ...
Tags: Pfizer, CHMP, anaplastic lymphoma kinase
Abbott will expand the current CE-IVD product labeling for its Vysis ALK Break Apart FISH Probe Kit to allow the test to be marketed in the European Union as a companion diagnostic. The test uses Abbott's proprietary fluorescence in situ ...
Tags: Abbott, anaplastic lymphoma kinase, ALK, FISH technology
BioView and Abbott have entered into a partnership agreement for the development of automated scanning solution to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in patients with advanced non-small cell lung cancer ...
Tags: BioView, Abbott, automated scanning solution, NSCLC
Pfizer Canada has announced the availability of Xalkori (crizotinib) for patients with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC) in Canada. A validated ALK assay should be used to ...
Tags: ALK, ALK-positive lung cancer, Pfizer Canada
The SFJ Pharmaceuticals Group (SFJ) has partnered with Pfizer to co-develop Dacomitinib as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of epidermal ...
Tags: Cancer Drug, cell lung cancer, therapy
Eli Lilly and Company Alimta(pemetrexed for injection)has received FDA approval for new use in the continuation maintenance setting for advanced or metastatic nonsquamous non-small cell lung cancer(NS NSCLC). The approval was based on ...
The US Patent and Trademark Office (USPTO) has granted patent No. 8,232,262 to Ziopharm Oncology's palifosfamide (ZIO-201). The patent covers palifosfamide compositions, formulations, methods of use and methods of manufacture, which now ...
Tags: USPTO, patent, Palifosfamide, cancer treatment drug
The US Patent and Trademark Office (USPTO) has issued a notice of allowance for CytRx Corporation's patent application covering a pharmaceutical composition of tamibarotene in capsule form. Tamibarotene is an orally available, ...
Tags: notice of allowance, patent application, tamibarotene, USPTO